Holista Colltech (ASX:HCT) entered into a binding supply and development deal with Regenerex Pharma to exclusively manufacture and supply its proprietary ovine collagen, including the 300 kDa intact collagen and nano-collagen technologies, for Regenerex's use in the development, clinical testing, and global distribution of advanced wound care products, according to a Tuesday Australian bourse filing.

Both companies will collaborate on new applications of nano-collagen in advanced wound care, with joint ownership of any resulting intellectual property. The agreement runs for the life of the relevant patents.

The agreement carries minimum purchase commitments for Regenerex of $50,000 in 2025, scaling to $3 million in 2026, $6 million in 2027, and $9 million annually from 2028 onwards.

Its shares rose 8% in recent trading on Tuesday.